ReviewEJIFCC2025
Evaluation of Metabolomics in Chemical Pathology Research in Pakistan: A Less Explored Path and New Frontier.
Review in EJIFCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolomics involves the study of unique chemical fingerprints left behind by specific cellular processes. Metabolomics encompasses the analysis of both "endogenous" compounds, such as amino acids, lipids, cofactors, nucleotides, carbohydrates, hormones, etc., and "exogenous" metabolites including drugs, toxins, environmental contaminants, pesticides, herbicides, etc. Initially, metabolic analyses heavily relied on nuclear magnetic resonance (NMR), but recent advancements in mass spectrometry (MS) and Tandem MS have expanded the horizons of research, service, and education in this field. In this overview, we delve into the domain of mass spectrometry from the perspective of Chemical Pathologists. To establish a baseline, we conducted a search using the PakMediNet search engine. Our literature review yielded a total of 1167 articles, of which 1155 were excluded, and 12 were included. Our findings indicated that while MS is utilized for method development and biomarker evaluation in the fields of basic biological sciences and the pharmaceutical industry, there are limited collaborative efforts with Chemical Pathologists for clinical applications. It is imperative to harness the advancements in MS for research and development, as this technology is a driving force behind progress in service and education. Looking ahead, areas such as newborn screening, diagnostics for inherited metabolic disorders, heavy metals analysis, and toxicology hold great potential for research in collaboration with Chemical Pathologists. To achieve these goals, the formation of working groups, establishing partnerships with institutes possessing relevant expertise, and providing funding opportunities are essential steps forward.
Indexed as
Identifiers
40584982PMC12205152What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.